Neurocrine Biosciences (NBIX) Misses Q1 EPS by 16c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.90), $0.16 worse than the analyst estimate of ($0.74). Non revenues reported.

"The Company did not report any revenue for the first quarter of 2017 compared to $15.0 million of revenue for the first quarter of 2016, which represented a milestone payment from AbbVie related to the commencement of Phase III studies of elagolix in uterine fibroids.."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lucid reports Q2 output, names new CFO and five other leaders
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform